IQ Consortium Drug-Induced Liver Injury Initiative: An Affiliate of the International Consortium for Innovation and Quality in Drug Development



The IQ-DILI Initiative is led by a Steering Committee composed of representatives from all member companies. The IQ-DILI Co-Chairs and Co-Chairs Elect represent their respective companies on the Steering Committee and form a Planning Committee charged with provides leadership and guidance in the management of the business and affairs of the consortium between meetings of the Steering Committee.

William Treem, MD, and Arie Regev, MD, serve as Co-Chairs of the IQ-DILI Initiative for 2017 - 2018. They will be succeeded by Daniel Seekins, MD, and John Marcinak, MD in 2019 - 2020.


William R. Treem, MD, IQ-DILI Initiative Co-Chair

Dr. William Treem is a trained pediatrician and pediatric gastroenterologist-hepatologist with a long career in academic pediatric gastroenterology as a clinician, clinical researcher, and teacher.  While in academic medicine, he focused on clinical research in children with rare inborn errors of metabolism affecting the liver and intestine; on new treatments for ulcerative colitis and Crohns disease in children; and on developing a new orphan drug as an enzyme replacement therapy for congenital sucrase-isomaltase deficiency.  Seven years ago, he joined Janssen and helped direct their pediatric drug development program for Aciphex resulting in a successful sNDA submission and approval for the treatment of GERD in children, and granting of pediatric exclusivity.  He joined the CHILD (Child Health Innovation and Leadership Department) 4.5 years ago, and is now a Senior Director of Pediatric Drug Development in CHILD; chairman of the Janssen Pediatric Center of Excellence; and also chairs the Janssen Hepatic Safety Group in the Global Medical Organization focused on drug-induced liver disease.  He is engaged in multiple pediatric drug development programs spanning all therapeutic areas, and is a leader in the effort to create a sustainable multispecialty-capable pediatric clinical trials network to facilitate pediatric drug development through the Innovative Medicines Initiative in Europe.    


Arie Regev, MD, IQ-DILI Initiative Co-Chair

The following is placeholder text known as “lorem ipsum,” which is scrambled Latin used by designers to mimic real copy. Nulla lectus ante, consequat et ex eget, feugiat tincidunt metus. Suspendisse nec congue purus.


John Marcinak, MD, IQ-DILI Initiative Co-Chair Elect

Dr. John Marcinak is Senior Medical Director, Global Patient Safety Evaluation at Takeda in Deerfield, IL. He received a BA in Chemistry at Youngstown State University, Ohio and MD from Ohio State University College of Medicine (Columbus, Ohio). Dr. Marcinak has 20 years of experience as a Pediatric Infectious Disease Specialist which includes Faculty positions at the University of Illinois at Chicago and University of Chicago as an Associate Professor of Pediatrics. At the University of Chicago, Dr. Marcinak was the Medical Director of the Pediatric and Adolescent HIV Program. Dr. Marcinak has 8 years of industry experience at Takeda in the area of Patient safety. His current focus at Takeda as a member of Global Patient Safety Evaluation is in support of the Marketed Products Group.

Dr. Marcinak represents Takeda on the IQ-DILI (Drug-Induced Liver Injury) Steering Committee and also as one of the IQ-DILI Co-Chair Elects. His interest in DILI began with involvement of a compound whose clinical development program was terminated in late phase due to liver safety. The formation of the IQ- DILI Initiative provides a unique opportunity for members of different pharmaceutical companies to collaborate and support each other to advance the science and knowledge in the area of DILI. This Initiative has the potential to result not only in providing benefit by increasing safety for individual patients but also provide important impact from a public health standpoint.


Daniel Seekins, MD, IQ-DILI Initiative Co-Chair Elect

The following is placeholder text known as “lorem ipsum,” which is scrambled Latin used by designers to mimic real copy. Donec eget risus diam. Sed a ligula quis sapien lacinia egestas. Donec eget risus diam.